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Abstract
Background: Chronic obstructive pulmonary disease (COPD) clinical trials evaluating hard endpoints (mortality,
hospitalized exacerbations) require a large number of subjects and prolonged observational periods. We hypothesized
that a composite endpoint of respiratory outcomes (CERO) can help evaluate safety and benefit in COPD trials.
Methods: Retrospective analysis of 5992 patients enrolled in the 4-year UPLIFT® trial, a randomized trial of tiotropium
versus placebo in patients with moderate-to-severe COPD. Patients were permitted to continue using their usual COPD
medications except for other anticholinergics. The CERO included deaths, respiratory failure, hospitalized exacerbations,
and trial dropout due to COPD worsening. The incidence rates (IRs) per 100 patient-years and risk ratios (RRs and 95 % CI)
were determined at years 1 to 4. The effect of treatments on CERO was similarly assessed. A power analysis helped
calculate the sample size needed to achieve outcome differences between treatments.
Results: The CERO IRs at years 1 to 4 for tiotropium versus placebo were 16, 13, 11, and 11, and 21, 16, 14, and 13,
respectively. The RRs of CERO between tiotropium and placebo at the same time points were: RR-year 0.76 (0.67, 0.86),
0.80 (0.72, 0.88), 0.81 (0.74, 0.89), and 0.84 (0.77, 0.92). Using the IRs and RRs, the sample size (alpha = 0.05 two-sided,
90 % power) for studies of 1, 2, 3, and 4 years would be 1546, 1392, 1216, and 1504 per treatment group, respectively,
with 575, 810, 930, 1383 required events, respectively, for hypothetical, event-driven studies.
Conclusions: A composite endpoint incorporating relatively infrequent serious or significant COPD-related safety
outcomes could be useful in clinical trials. In UPLIFT®, CERO events were significantly reduced in patients receiving
tiotropium compared with placebo.
Trial registration: NCT00144339.
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Background
Chronic obstructive pulmonary disease (COPD) clinical
trials evaluating relatively infrequent endpoints such as
mortality, respiratory failure, and/or hospitalized exacer-
bations are, of necessity, often large and require follow-
up of patients over prolonged periods of time [1–3].
Indeed, recent trials evaluating mortality as the outcome,
such as the Tiotropium Safety and Performance in
Respimat® (TIOSPIR®) study [3] or the Study to Under-
stand Mortality and Morbidity in COPD (SUMMIT) [4],
recruited more than 16,000 patients in order to have
sufficient power to determine the significance of the
outcomes.
Facing a similar situation, studies in other medically
relevant fields have integrated infrequently occurring
events into composite endpoints that have proven rele-
vant to the planning of clinical trials and the likely bene-
fit of treatment to patients [5–9]. This is particularly
relevant in the field of cardiology, where a composite
measure of major adverse cardiac events (MACE) has
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become a frequent endpoint for therapeutic trials [5, 6, 10].
Composite endpoints have also been used in infectious dis-
eases (including tuberculosis [7]), in stroke [11], collagen
vascular disease [12], multiple sclerosis [9], diabetes [8],
and renal failure [6]. In COPD, a composite endpoint for
safety in an endobronchial valve trial for emphysema was
evaluated [13].
Using data from a large-scale clinical trial in patients
with moderate to very severe COPD [2], we explored
three hypotheses. First, that four important individual
outcomes in COPD—death, hospitalized exacerbations,
respiratory failure, and withdrawal from the study due to
worsening COPD—could be integrated into a composite
endpoint. Second, that there are measurable differences
in the composite endpoint incidence between an active
and a control arm. And third, that based on these results,
fewer patients would need to be recruited to achieve suffi-
cient power to explore significant effects of interventions
on these outcomes. These hypotheses were tested using
data from the UPLIFT® (Understanding Potential Long-
term Impacts on Function with Tiotropium) trial, which
included patients with COPD who were permitted to con-
tinue using their usual COPD medications, except for
other inhaled anticholinergics [2].
Methods
UPLIFT® (ClinicalTrials.gov number, NCT00144339)
was an international, multicenter, 4-year, randomized,
placebo-controlled trial of tiotropium in patients with
COPD, the details of which were previously published
[2, 14, 15]. Patients were recruited from 490 centers in
37 countries. In brief, patients were aged ≥40 years,
with a smoking history of ≥10 pack-years, postbroncho-
dilator forced expiratory volume in 1 s (FEV1) of ≤70 %
of predicted, and FEV1 to forced vital capacity (FVC)
ratio of <0.70 of predicted. Exclusion criteria included a
history of asthma, COPD exacerbation, or respiratory
infection within 4 weeks of screening, prior pulmonary
resection, and use of supplemental oxygen for >12 h/day.
Using centralized randomization by country and by site,
patients were randomized to 18 μg tiotropium or placebo
(control) (once daily). All respiratory medications, with
the exception of other inhaled anticholinergics, were
permitted throughout the trial. Postrandomization cli-
nic visits occurred at 1 month, at 3 months, and every
3 months throughout the 4-year treatment period. All
patients gave written informed consent and the study
was approved by local ethical review boards and con-
ducted in accordance with the Declaration of Helsinki.
Composite Endpoint of Respiratory Outcomes (CERO) and
statistical analysis
As part of the study, safety endpoints were carefully reg-
istered; causes of death were assessed by the mortality
adjudication committee [16]. The composite outcomes
endpoint included fatal events (all-cause mortality); severe
ventilatory failure, defined as patients requiring noninva-
sive or invasive mechanical ventilation and/or hypercapnia
as documented in arterial blood gases; severe exacerba-
tions, defined as episodes requiring hospitalization from
COPD; and discontinuations from the trial due to worsen-
ing COPD. The onset of the first event from the compos-
ite endpoint is used to calculate the incidence rate. All
patients recruited into the study were included in the ana-
lysis for the events of mortality, severe respiratory failure,
hospitalizations for COPD, and discontinuation of the
study for worsening COPD while on treatment within the
study period (within 30 days of last intake of study medi-
cation). The analysis of the composite endpoint in this
study only included on-treatment fatal events. Although
fatal events were recorded beyond the treatment period in
UPLIFT®, nonfatal events were not, so that vital status for
this period was not included. Incidence rates (IRs) per 100
patient-years and risk ratios (RRs) were determined at 1,
2, 3, and 4 years. Incidence rates were calculated using the
ratio of number of patients with the event and time at risk.
Under the conditions of an event-driven trial, sample size
was calculated assuming exponential survival function as
the total number of events needed to achieve a given stat-
istical power for an expected RR (or hazard ratio [HR])
and type I error. Under the conditions of a trial with fixed
treatment duration, such as UPLIFT®, number of events
was first calculated for a given RR by log-rank test. Num-
ber of patients was derived based on the number of
events, IR, and treatment duration. For both designs, it
was assumed that patients will be followed up for CERO
events after discontinuation of the study according to the
intent-to-treat principle. Therefore, sample size was not
adjusted for possible dropouts. Statistical software nQuery
was used to calculate the sample sizes.
Results
Baseline characteristics
Altogether, 5992 patients were randomized and received
study medication. The baseline characteristics were bal-
anced between treatment groups (Table 1); there were no
differences in comorbidity data between the two treatment
groups. Mean age was 65 years, 75 % were men, 30 % were
current smokers, and mean postbronchodilator FEV1 was
1.32 L (47.6 % predicted). The patients had a wide range
of airflow limitation and on average had significant im-
pairment in their health status scores.
Composite Endpoint of Respiratory Outcomes (CERO)
The survival event curve (Kaplan–Meier) for the CERO
endpoint shows a separation throughout the study in
favor of tiotropium (Fig. 1). The IRs and RRs of the
CERO endpoints were consistently and significantly
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lower with tiotropium vs placebo for all 4 years (Table 2).
The same was observed for the individual events of re-
spiratory failure, hospitalizations for exacerbations, and
discontinuation from the trial due to COPD, but not for
death, for which the RRs were significant for years 3 and
4, but not significant for years 1 and 2 (Table 3).
The effects of tiotropium versus placebo on the inci-
dence of CERO were significant in most patients, includ-
ing the 2007 Global Initiative for Chronic Obstructive
Lung Disease (GOLD) stage [17] III and IV patients
(year 1 − 4) (Table 4).
Calculation of sample size
Using the RRs at 1, 2, 3, and 4 years as the expected
HRs in a survival analysis, in a hypothetical event-driven
study, the sample size (alpha = 0.05 two-sided, 90 %
power) as represented in number of events would be
575, 810, 930, and 1383 for the HRs of 0.76, 0.80, 0.81,
and 0.84, respectively, per treatment group (Table 5).
Sample sizes were calculated based on the estimated
RRs and the IRs provided in Tables 2, 3 and 4. The num-
ber of patients to enroll varies depending on the length
of the study, including enrollment period. For example,
for a HR of 0.76, if the enrollment is 1 year and the
maximum length of follow-up is 2 years, then the num-
ber of patients would be 1205 per group to achieve 575
events, assuming all patients will be followed up for the
composite safety endpoint until study completion. With
the same HR, 1-year enrollment, and maximum follow-
up of 3 years, the number of patients will reduce to 786
per group to achieve the expected 575 events. The sam-
ple sizes with the composite endpoint (GOLD stages II,
III, IV, and total group) at 80 % power, 85 % power, and
90 % power showed differences depending on the GOLD







Male, % 75 74 75
Mean (SD) age, y 65 (8) 65 (8) 65 (8)
Current smoker, % 29 30 30
Mean (SD) duration of COPD, y 10 (8) 10 (7) 10 (7)
GOLD stage, %
II 46 45 46
III 44 44 44
IV 8 9 9
Mean (SD) prebronchodilator
FEV1, L 1.1 (0.4) 1.1 (0.4) 1.1 (0.4)
FEV1, % predicted value 40 (12) 39 (12) 39 (12)
FVC, L 2.6 (0.8) 2.6 (0.8) 2.6 (0.8)
FEV1/FVC ratio, % 42 (11) 42 (11) 42 (11)
Mean (SD) postbronchodilator
FEV1, L 1.3 (0.4) 1.3 (0.4) 1.3 (0.4)
FEV1, % predicted value 48 (13) 47 (13) 48 (13)
FVC, L 3.1 (0.9) 3.1 (0.9) 3.1 (0.9)
FEV1/FVC ratio, % 44 (11) 43 (11) 43 (11)
Mean (SD) SGRQ total
score, units
46 (17) 46 (17) 46 (17)
Patients with comorbidities,
n (%)
Vascular disorders 1353 (45.3) 1367 (45.5) 2720 (45.4)
Cardiac disorders 790 (26.5) 765 (25.5) 1555 (26.0)
Respiratory, thoracic and
mediastinal disorders
565 (18.9) 593 (19.7) 1158 (19.3)
COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in
1 s, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive
Lung Disease, SD standard deviation, SGRQ St George’s Respiratory Questionnaire
Fig. 1 Kaplan–Meier survival event curve for the composite CERO endpoint (tiotropium vs placebo)
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stage (Table 5). Sample sizes were calculated based on
the estimated RRs and the IRs provided in Tables 2, 3
and 4. Using the IRs and RRs as the expected outcome,
the sample size (alpha = 0.05 two-sided, 90 % power) at
1, 2, 3, and 4 years would then be 1546, 1392, 1216, and
1504 per treatment group, respectively.
Discussion
This analysis of data obtained in UPLIFT® yielded three
important findings. First, a COPD composite endpoint
incorporating infrequent serious or significant COPD-
related safety outcomes can be useful to demonstrate
efficacy and safety in clinical trials. Second, in the UP-
LIFT® trial, the IRs of CERO events were significantly re-
duced in patients receiving tiotropium compared with
placebo [2]. Third, this approach may help plan studies
incorporating efficacy and safety evaluation with a rea-
sonable sample size and shorter time.
Randomized clinical trials represent the gold standard
to evaluate the comparative efficacy and safety of novel
therapies, especially pharmacological drugs. For highly
prevalent and deadly diseases, potential therapies should
be evaluated by their impact on important clinical end-
points. An example is COPD, a disease that constitutes
one of the top four causes of death in the world and that
in its more severe cases results in hospital admissions,
which increase personal and societal costs. However, al-
though COPD causes many deaths because of its high
prevalence, its long natural course, and the relatively low
incidence of deaths or hospitalized exacerbations has re-
sulted in the need to complete studies with very large
numbers of patients and over a long period. Thus, the
TORCH (Towards a Revolution in COPD Health) and
the UPLIFT® studies, which recruited ~6000 patients each,
lasted 3 and 4 years, respectively; and the mortality and
hospitalization rate signals were relatively weak [1, 2].
Based on those results, two other trials (TIOSPIR® and
SUMMIT) evaluating mortality as an outcome needed to
recruit more than 16,000 patients each to have sufficient
power to address the impact of these interventions on
mortality and hospitalized exacerbations [3, 4]. An alter-
native approach used in other fields with a high burden of
disease that may be divided into several outcomes that by
themselves are relatively rare has been integrating import-
ant clinical outcomes into a composite endpoint that can
then represent a more comprehensive measure of the
overall response to therapy from a safety perspective. Al-
though most studies have been done in the general field of
cardiology [10, 13, 15, 18, 19], there have been many re-
ports of trials using composite endpoints in infectious dis-
eases (including tuberculosis [7]) as well as in stroke [11],
diabetes [8], rheumatoid arthritis [20], and renal failure
[6], among others. Only one study used a composite end-
point to evaluate the safety of endobronchial valves [13].
Interestingly, some COPD studies used the composite
endpoint MACE as a safety composite endpoint, but
this was done to evaluate cardiac safety in COPD pa-
tients [2, 3, 21–23].
We selected four hard endpoints because of their
clinical validity and registered accuracy in this regard;
we not only included all-cause mortality (an accepted
patient-centered outcome), but also hospitalizations for
exacerbations of COPD and respiratory failure. We con-
sidered that these latter two outcomes were appropriately
associated with all-cause mortality to add strength to the
observed results. Similarly, we included discontinuation
from the study due to COPD worsening because this
event in long clinical trials represents an important signal
of decompensation of the target organ and relates to the
patients’ own feelings regarding their deteriorating health
[24]. We integrated all of the outcomes into the CERO
and explored its value in the UPLIFT® study database.
The results of the study indicate a significant effect
on the composite index that was of only borderline
Table 2 IR of the CERO endpoint in all patients enrolled in UPLIFT® study on years 1 to 4 of the study
Tiotropium (n = 2986) Control (n = 3006) Tiotropium/control
Year N (%) Patient -year IRa N (%) Patient-year IRa RR-year p-value
(95 % CI)
1 436 (15) 2711.4 16.1 556 (19) 2637.5 21.1 0.76 <0.0001
(0.67–0.86)
2 664 (22) 5146.1 12.9 803 (27) 4959.0 16.2 0.80 <0.0001
(0.72–0.88)
3 843 (28) 7373.7 11.4 992 (33) 7059.6 14.1 0.81 <0.0001
(0.74–0.89)
4 995 (33) 9442.9 10.5 1128 (38) 9007.5 12.5 0.84 0.0001
(0.77–0.92)
N = number of events
CI confidence interval, IR incidence rate, RR risk ratio
aPer 100 patient-years
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Table 3 IRs and RRs of the individual events included in the composite COPD endpoint CERO in placebo and tiotropium groups
over a 4-year period
Tiotropium (n = 2986) Control (n = 3006) Tiotropium/control
Event by year N (%) Patient-year IRa N (%) Patient-year IRa RR-year p-value
(95 % CI)
Fatal event
1 162 (5) 2675.7 6.1 182 (6) 2576.8 7.1 0.86 0.1538
(0.69-1.06)
2 238 (8) 5067.4 4.7 261 (9) 4797.4 5.4 0.86 0.1010
(0.72-1.03)
3 307 (10) 7222.9 4.3 339 (11) 6741.5 5.0 0.85 0.0328
(0.72-0.99)
4 376 (13) 9169.5 4.1 408 (14) 8459.5 4.8 0.85 0.0232
(0.74-0.98)
Serious adverse event: Respiratory failure
1 31 (1) 2726.9 1.1 51 (2) 2626.3 1.9 0.59 0.0187
(0.37-0.91)
2 48 (2) 5152.6 0.9 67 (2) 4866.5 1.4 0.68 0.0389
(0.47-0.98)
3 68 (2) 7324.4 0.9 88 (3) 6809.8 1.3 0.72 0.0406
(0.52-0.99)
4 83 (3) 9267.4 0.9 112 (4) 8513.8 1.3 0.68 0.0079
(0.51-0.90)
Serious adverse event: Hospitalization due to exacerbation
1 272 (9) 2630.9 10.3 326 (11) 2513.9 13.0 0.80 0.0058
(0.68-0.94)
2 440 (15) 4825.7 9.1 507 (17) 4515.4 11.2 0.81 0.0014
(0.71-0.92)
3 573 (19) 6701.1 8.6 641 (21) 6161.6 10.4 0.82 0.0006
(0.73-0.92)
4 681 (23) 8308.8 8.2 735 (25) 7555.3 9.7 0.84 0.0013
(0.76-0.94)
Trial discontinuation due to worsening of COPD
1 92 (3) 2741.3 3.4 178 (6) 2644.4 6.7 0.50 <0.0001
(0.39-0.64)
2 146 (5) 5179.9 2.8 250 (8) 4906.4 5.1 0.55 <0.0001
(0.45-0.68)
3 202 (7) 7366.6 2.7 317 (11) 6871.0 4.6 0.59 <0.0001
(0.50-0.71)
4 237 (8) 9326.7 2.5 367 (12) 8598.9 4.3 0.60 <0.0001
(0.51-0.70)
N = number of events
CI confidence interval, COPD chronic obstructive pulmonary disease, IR incidence rate, RR risk ratio
aPer 100 patient-years
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significance for the individual outcome of mortality in
the original report [2]. Indeed, in this regard, neither
UPLIFT® nor the TORCH trial has been considered as
having shown a significant impact on mortality using
mortality including vital status follow-up of discontin-
ued patients [1, 2]. Several authors have criticized the
use of composite endpoints when there are contradic-
tions among the results for the individual components
and when they are not clearly defined. This is not the
case in the current study. As seen in Tables 2 and 3,
the tiotropium arm showed a significant impact on the
incident rate ratio for CERO compared with placebo,
and the RRs for each of the individual components sup-
ported the beneficial effect. Further, the results were
applicable across a wide range of airflow obstruction
(Table 4), supporting general application of the results,
at least for patients meeting the criteria for inclusion in
UPLIFT®.
Perhaps the most important information provided by
the current study is the power calculation of the number
Table 4 IR and RR of the occurrence of CERO in tiotropium and placebo groups for GOLD stage II, and combined GOLD stages III
and IV over a 4-year period
GOLD stage II
Tiotropium (n = 1554) Control (n = 1602) Tiotropium/control
Year N (%) Patient-year IRa N (%) Patient-year IRa RR p-value
(95 % CI)
1 114 (7) 1312.9 8.7 158 (10) 1255.7 12.6 0.69 0.0025
(0.54–0.88)
2 187 (12) 2543.0 7.4 242 (15) 2408.5 10.0 0.73 0.0013
(0.60–0.89)
3 249 (16) 3709.7 6.7 312 (20) 3483.4 9.0 0.75 0.0007
(0.63–0.89)
4 304 (20) 4818.7 6.3 361 (23) 4501.6 8.0 0.79 0.0021
(0.68–0.92)
GOLD stage III/IV (combined)
Tiotropium (n = 1554) Control (n = 1602) Tiotropium/control
Year N (%) Patient-year IRa N (%) Patient-year IRa RR p-value
(95 % CI)
1 315 (20) 1354.3 23.3 385 (24) 1340.5 28.7 0.81 0.0055
(0.70–0.94)
2 465 (30) 2520.0 18.5 541 (34) 2476.8 21.8 0.84 0.0077
(0.75–0.96)
3 579 (37) 3547.6 16.3 659 (41) 3474.6 19.0 0.86 0.0084
(0.77–0.96)
4 675 (43) 4475.1 15.1 743 (46) 4378.0 17.0 0.89 0.0266
(0.80–0.99)
N = number of events
CI confidence interval, GOLD Global Initiative for Chronic Obstructive Lung Disease, IR incidence rate, RR risk ratio
aPer 100 patient-years
Table 5 Number of events needed to explore the effect of
therapy in patients with COPD
Events
Power (%) Year GOLD II GOLD III GOLD IV Overall
80 1 226 845 436 429
2 331 1367 638 605
3 375 1467 1244 695
4 546 2538 1499 1033
85 1 259 967 499 491
2 379 1564 730 692
3 429 1678 1423 795
4 625 2903 1714 1181
90 1 303 1131 584 575
2 443 1830 854 810
3 503 1964 1666 930
4 731 3397 2006 1383
The calculations were made with a power of 80 %, 85 %, and 90 % at p < 0.05
GOLD Global Initiative for Chronic Obstructive Lung Disease
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of subjects and the duration of the trial needed to obtain
a significant result for a therapeutic intervention. Again,
using the results from UPLIFT® and the composite
measure of CERO, significant reduction in the social and
economic cost of completing such trials is theoretically
possible.
Using the IRs and RRs as the expected outcome, the
sample sizes are certainly much smaller than the SUMMIT
trial (16,000 patients) and the completed TIOSPIR® (17,135
patients) study, in which all-cause mortality was the pri-
mary endpoint. As the number of medications approved
for the treatment of COPD and the benefits that are re-
ported to support their routine use increase, ethical reasons
will preclude the completion of long-term trials with a
placebo-control arm. Thus, comparison trials may prove to
be the way of the future, and the larger signals from com-
posite endpoints a potentially useful tool to evaluate the re-
sults of those trials.
We recognize limitations to this study. First, it is a
retrospective analysis of data collected for a study in
which the primary endpoint was rate of decline of lung
function, and the composite endpoint could only be de-
rived from endpoints reported in the study. However,
mortality (carefully reviewed by a clinical endpoint com-
mittee) was a predetermined endpoint of the study. In
addition, respiratory failure and severe exacerbation used
in this report were collected as adverse events and the
cause for discontinuation of the study carefully recorded.
Indeed, we believe careful accounting for the differential
dropout from clinical trials represents the strength of
this analysis because those patients who discontinue the
trial prematurely due to worsening disease [20] are char-
acterized by worse patient-related outcomes. Further-
more, patients dropping out from the placebo group
have worse patient-related outcomes than those drop-
ping out from the active treatment group. Second, the
elements used to define CERO were chosen after the
study was completed. However, these were selected be-
cause of their clinical validity, careful recording, and
value as reflecting the impact of COPD on the patients
themselves. Third, the analysis was an on-treatment ana-
lysis based on data collected during the treatment period.
The intent-to-treat analysis was not feasible because two
components of the CERO, severe respiratory failure and
severe exacerbation, were not collected after treatment
discontinuation. This likely caused an unfavorable bias
against tiotropium because more patients discontinued
from placebo than from tiotropium; thus, more events in
the placebo arm may otherwise have been recorded had
the discontinued patients been followed up. Nevertheless,
the exposure was adjusted in the calculation of IR and
RR in an attempt to address such bias. If the composite
endpoint is used as the primary endpoint in a future
study, we recommend that all components are followed
up after treatment discontinuation in a true intent-to-
treat analysis.
Conclusions
This study shows that a composite endpoint incorpor-
ating infrequent serious or significant COPD-related
safety outcomes could be useful in clinical trials. This
clinically meaningful approach may help in the design
of studies incorporating safety with a feasible sample
size; however, further validation of the composite end-
point will be required. In the UPLIFT® trial, the IRs of
CERO events were significantly reduced in patients
receiving tiotropium.
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